Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939275 · ClinicalTrials.gov registry record · NA
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
A NA study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01939275: Completed NA study, sponsored by City of Hope Medical Center.
NCT01939275 is a NA study that has completed, run by City of Hope Medical Center. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01939275, a NA study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may help doctors study the characteristics of tumors and choose the best treatment.
Primary Outcome
The reading of the 64CuDOTA-trastuzumab-PET imaging of the study subjects were performed by two radiologists, one who read the first scan and the second nuclear radiologist read the remaining seven scans. To eliminate potential bias, the second nuclear radiologist was blinded to the HER2 status of the tumors as well as the location of the tumor until radiolabeled uptake was measured. XD (version 3.6; Miranda Medical) was used for image analysis.Tumor visualized as "hot" relative to adjacent tiss
Interventions
- PROCEDURE Computed Tomography
- OTHER laboratory biomarker analysis
- RADIATION copper Cu 64-DOTA-trastuzumab
- DEVICE positron emission tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-11-19 |
| Est. Completion | 2024-08-05 |
| Phase | NA |
What the finished NCT01939275 record still lists
NCT01939275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT01939275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01939275 about?
NCT01939275 is a clinical study titled "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer". This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may ...
What is the current status of trial NCT01939275?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2014-11-19. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT01939275?
The interventions under investigation include: Computed Tomography (PROCEDURE), laboratory biomarker analysis (OTHER), copper Cu 64-DOTA-trastuzumab (RADIATION), positron emission tomography (DEVICE).
Who is sponsoring clinical trial NCT01939275?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01939275's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI